114027
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
拉莫三嗪联合左乙拉西坦治疗癫痫患者的疗效及其对海马体积和神经炎症反应的影响
Authors Li P, Qi A, Ma J, Li A, Sun Z
Received 1 July 2025
Accepted for publication 13 October 2025
Published 20 December 2025 Volume 2025:18 Pages 17843—17851
DOI https://doi.org/10.2147/JIR.S546974
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Dharmappa Krishnappa
Puxian Li,1 Aihong Qi,2 Jinyuan Ma,1 Aijun Li,1 Zhen Sun1
1Department of Neurosurgery, Affiliated Hospital of Qingdao Binhai University, Qingdao, 266404, People’s Republic of China; 2Department of Nursing, Affiliated Hospital of Qingdao Binhai University, Qingdao, 266404, People’s Republic of China
Correspondence: Aihong Qi, Email q21wtk@163.com
Objective: To analyze the efficacy of combined lamotrigine and levetiracetam therapy in epileptic patients and its impact on hippocampal volume and inflammatory response.
Methods: A retrospective analysis was conducted on the clinical data of 120 epileptic patients admitted to our hospital from December 2022 to February 2024. All patients met the inclusion and exclusion criteria. Based on the treatment received, patients were divided into a control group (n=60, treated with lamotrigine) and an observation group (n=60, treated with lamotrigine combined with levetiracetam). Clinical efficacy, bilateral hippocampal volume, inflammatory factors, brain injury markers, and adverse reactions were compared between the two groups.
Results: ① Clinical efficacy: The observation group had higher effective rates in seizure control and EEG epileptiform discharge improvement than the control group (P< 0.05). ② Hippocampal volume: No significant differences were observed in bilateral hippocampal volume changes between the two groups before and after treatment (P> 0.05). ③ Inflammatory factors: TNF-α, hs-CRP, and IL-6 levels decreased in both groups after treatment, with greater reductions in the observation group (P< 0.05). ④ Brain injury markers: S-100β and HMGB-1 levels decreased in both groups after treatment, with greater reductions in the observation group (P< 0.05). ⑤ Adverse reactions: The incidence of adverse reactions was comparable between the two groups (P> 0.05).
Conclusion: Compared with lamotrigine monotherapy, lamotrigine combined with levetiracetam further improves treatment efficacy in epileptic patients, reduces inflammatory response and brain injury, and does not increase the risk of adverse reactions.
Keywords: lamotrigine, levetiracetam, epilepsy, treatment outcome, hippocampal volume, neuroinflammation
1Department of Neurosurgery, Affiliated Hospital of Qingdao Binhai University, Qingdao, 266404, People’s Republic of China; 2Department of Nursing, Affiliated Hospital of Qingdao Binhai University, Qingdao, 266404, People’s Republic of China
Correspondence: Aihong Qi, Email q21wtk@163.com
Objective: To analyze the efficacy of combined lamotrigine and levetiracetam therapy in epileptic patients and its impact on hippocampal volume and inflammatory response.
Methods: A retrospective analysis was conducted on the clinical data of 120 epileptic patients admitted to our hospital from December 2022 to February 2024. All patients met the inclusion and exclusion criteria. Based on the treatment received, patients were divided into a control group (n=60, treated with lamotrigine) and an observation group (n=60, treated with lamotrigine combined with levetiracetam). Clinical efficacy, bilateral hippocampal volume, inflammatory factors, brain injury markers, and adverse reactions were compared between the two groups.
Results: ① Clinical efficacy: The observation group had higher effective rates in seizure control and EEG epileptiform discharge improvement than the control group (P< 0.05). ② Hippocampal volume: No significant differences were observed in bilateral hippocampal volume changes between the two groups before and after treatment (P> 0.05). ③ Inflammatory factors: TNF-α, hs-CRP, and IL-6 levels decreased in both groups after treatment, with greater reductions in the observation group (P< 0.05). ④ Brain injury markers: S-100β and HMGB-1 levels decreased in both groups after treatment, with greater reductions in the observation group (P< 0.05). ⑤ Adverse reactions: The incidence of adverse reactions was comparable between the two groups (P> 0.05).
Conclusion: Compared with lamotrigine monotherapy, lamotrigine combined with levetiracetam further improves treatment efficacy in epileptic patients, reduces inflammatory response and brain injury, and does not increase the risk of adverse reactions.
Keywords: lamotrigine, levetiracetam, epilepsy, treatment outcome, hippocampal volume, neuroinflammation